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Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends
a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological
treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2,
and -4 studies to evaluate the efficacy and safety of the dual bronchodilator fixed-dose combination
glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-
suspension delivery technology, in GOLD category A patients with moderate-to-very severe
COPD.
Materials and Methods: PINNACLE-1, -2, and -4 were Phase III, randomized, double-blind,
parallel-group, multicenter studies (NCT01854645, NCT01854658, and NCT02343458). Patients
received 24 weeks’ treatment with GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg,
formoterol fumarate (FF) MDI 9.6 µg, or placebo MDI twice daily. GOLD category A patients
were identified based on a COPD Assessment Test score of <10 and exacerbation history in the
previous year (none/one not requiring hospitalization). Endpoints evaluated were change from
baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1), peak change
from baseline in FEV1 within 2 hrs post-dose, and adverse events (AEs).
Results: The pooled intent-to-treat population comprised 729 GOLD category A patients.
GFF MDI significantly improved morning pre-dose trough FEV1 at Week 24 versus GP MDI,
FF MDI, and placebo MDI (least squares mean [LSM] differences 54 mL, 62 mL, and 188 mL,
respectively; all p≤0.0053), and peak FEV1 atWeek 24 versus GPMDI, FFMDI, and placeboMDI
(LSM differences 124 mL, 104 mL, and 307 mL, respectively; all p<0.0001). Improvements over
24 weeks were comparable to at Week 24. The AE profile of GFF MDI in GOLD category
A patients was similar to monocomponents and placebo MDI.
Conclusion: GFF MDI significantly improved lung function versus monocomponents and
placebo MDI in GOLD category A patients with moderate-to-very severe COPD, with no
unexpected safety findings.
Keywords: β2-agonist, bronchodilator, COPD, co-suspension delivery technology, lung
function, muscarinic antagonist
Introduction
In their 2011 report, the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) introduced categorizing patients with COPD based on their symptom
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burden and exacerbation risk.1 In this schema, GOLD
category A patients have a low symptom burden and
a low risk of exacerbations.2 A low symptom burden is
defined as a COPD Assessment Test (CAT)3 score of <10
or a modified Medical Research Council (mMRC)4 score
of <2,2 and a low risk of exacerbations is defined as no
exacerbations or one moderate exacerbation (i.e., not
leading to hospitalization) in the previous year.2
The GOLD 2020 report suggests that the GOLD cate-
gories may be used to guide initial pharmacological treat-
ments for patients, with the most recent strategy proposing
that GOLD category A patients are treated with a single
short-acting bronchodilator or a single long-acting broncho-
dilator when starting pharmacological treatment.2 Dual
bronchodilator therapy with a long-actingmuscarinic antago-
nist (LAMA) plus a long-acting β2-agonist (LABA) as an
initial therapy is recommended for highly symptomatic
GOLD category D patients who have a high risk of exacer-
bations, and may be considered as an initial therapy for
GOLD category B patients who have a low risk of exacer-
bations and severe breathlessness.2 Dual LAMA/LABA ther-
apy is also recommended as a step-up treatment from long-
acting bronchodilator monotherapy for patients with persis-
tent breathlessness or exercise limitation, and for patients
with persistent exacerbations, particularly those with low
blood eosinophil levels.2
Many Phase III studies investigating LAMA/LABA
fixed-dose combinations (FDCs) have excluded patients
with a low symptom burden, for example, those defined
by an mMRC score of <2,5–8 thereby excluding GOLD
category A patients.2 The PINNACLE Phase III clinical
trial program has demonstrated the efficacy and safety
of the dual LAMA/LABA FDC glycopyrrolate/formo-
terol fumarate metered dose inhaler (GFF MDI; Bevespi
Aerosphere®), formulated using co-suspension delivery
technology, in patients with moderate-to-very severe
airflow obstruction who were not required to have
a high symptom burden at study entry.9–11 Therefore,
this allowed a pooled analysis of PINNACLE-1, -2, and
-4 to evaluate the effects of GFF MDI on lung function
and safety in GOLD 201712 category A patients with
COPD who had moderate-to-very severe airflow
obstruction. We hypothesized that this patient popula-
tion would benefit from dual LAMA/LABA therapy. To
our knowledge, the efficacy and safety of a LAMA/
LABA FDC has rarely been studied in GOLD category
A patients.
Materials and Methods
Study Design
PINNACLE-1, -2, and -4 (NCT01854645, NCT01854658,
and NCT02343458) were Phase III randomized, double-
blind, placebo-controlled, parallel-group, multicenter studies
(Figure 1).9,11 PINNACLE-1 was conducted in the USA,
Australia, and New Zealand; PINNACLE-2 was conducted
in the USA; and PINNACLE-4 was conducted in Asia,
Europe, and the USA.
Patients received 24 weeks of treatment with GFF MDI
18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol
fumarate (FF) MDI 9.6 µg, or placebo MDI twice daily in
all studies. PINNACLE-1 included an additional treatment
arm in which patients received open-label tiotropium bro-
mide 18 µg dry-powder inhaler (DPI) once daily (Spiriva®
HandiHaler®). Patients who were receiving a stable dose of
inhaled corticosteroid (ICS) at screening were permitted to
continue its use throughout the studies.
Patients provided written informed consent prior to
screening, and the studies were conducted in accordance
with Good Clinical Practice, including the Declaration of
Helsinki and the International Council for Harmonisation.
The protocols were approved by local institutional review
boards, as previously reported for each study (Table S1).9,11
Patient Population
Key inclusion and exclusion criteria have been previously
described.9,11 Briefly, patients were current or former smokers
(≥10 pack-years) who were 40–80 years of age, with an estab-
lished clinical history of COPD as defined by the American
Thoracic Society/European Respiratory Society.13 Patients
GFF MDI (N=217)
24-week double-blind treatment period
Follow-
up
phone
call
GP MDI (N=195)
FF MDI (N=204)
Tiotropium DPIa (N=62)
Placebo MDI (N=113)
Screening
Day –28 to Day –1 Visits: Day 1, Week 2, 4, 8, 12, 16, 20, and 24
Randomization
Figure 1 Study Flow Diagram for GOLD Category A Patients in PINNACLE-1,
-2, and -4.
Notes:N indicates the number of GOLD categoryA patients in each treatment arm. aThe
open-label tiotropiumbromide18μgDPI treatment armwasonly included inPINNACLE-1.
Abbreviations: DPI, dry-powder inhaler; FF, formoterol fumarate; GFF, glycopyr-
rolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung
Disease; GP, glycopyrrolate; MDI, metered dose inhaler.
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were required to have a post-bronchodilator forced expiratory
volume in 1 second (FEV1)/forced vital capacity ratio of <0.70,
and an FEV1 of <80% predicted normal (FEV1 ≥750 mL if
<30% predicted normal).
There were no inclusion criteria related to baseline symp-
tom burden or exacerbation history. Patients were categorized
as GOLD A if they had a CAT score of <10 at screening, and
either no exacerbations or one exacerbation that did not lead to
hospitalization in the previous year.12
Lung Function Outcomes
Subgroup analysis by GOLD category was performed in
the pooled intent-to-treat (ITT) population for the lung
function endpoints of change from baseline in morning
pre-dose trough FEV1 (primary endpoint in all studies),
and peak change from baseline in FEV1 within 2 hrs post-
dose (secondary endpoint in all studies), which were the
only endpoints that were pre-specified in the integrated
analyses. Baseline FEV1 was defined as the mean of all
evaluable 60- and 30-min pre-dose values on Day 1 of
treatment.
Safety
Treatment-emergent adverse events (TEAEs) were monitored
throughout the studies, and a subgroup analysis of TEAEs by
GOLD category was performed for the pooled studies.
Statistical Analyses
The pooled ITT population included all patients who were
randomized and received any amount of study treatment,
analyzed according to treatment assigned. The pooled safety
population included patients who were randomized and
received any amount of study treatment, analyzed according
to treatment received. The tiotropium DPI treatment arm
from the PINNACLE-1 study was not included in these
pooled analyses since this treatment arm was only present
in one of the three studies, tiotropium was administered
open-label, and only a small number of GOLD category
Table 1 Baseline Demographic and Clinical Characteristics for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017
Category A Patients (ITT Population)
GFF MDI 18/9.6 µg
(N=217)
GP MDI 18 µg
(N=195)
FF MDI 9.6 µg
(N=204)
Placebo MDI
(N=113)
Overall
(N=729)
Mean age (SD), years 65.7 (7.2) 64.9 (8.0) 65.2 (7.8) 66.5 (7.4) 65.5 (7.6)
Male, n (%) 157 (72.4) 149 (76.4) 148 (72.5) 76 (67.3) 530 (72.7)
Mean BMI (SD), kg/m2 26.1 (5.3) 26.0 (5.1) 25.5 (4.9) 25.9 (5.6) 25.9 (5.2)
Race, n (%)
White 131 (60.4) 118 (60.5) 115 (56.4) 69 (61.1) 433 (59.4)
Asian 79 (36.4) 65 (33.3) 81 (39.7) 38 (33.6) 263 (36.1)
Other 7 (3.2) 12 (6.2) 8 (3.9) 6 (5.3) 33 (4.5)
Mean total CAT scorea (SD) 6.5 (2.2) 6.4 (2.2) 6.5 (2.1) 6.7 (2.3) 6.5 (2.2)
Used ICS at baseline, n (%) 57 (26.3) 59 (30.3) 67 (32.8) 37 (32.7) 220 (30.2)
Current smoker, n (%) 76 (35.0) 66 (33.8) 58 (28.4) 39 (34.5) 239 (32.8)
Mean number of pack-years smokedb (SD) 47.5 (26.6) 43.6 (25.1) 45.9 (23.7) 45.0 (24.9) 45.6 (25.1)
COPD severityc, n (%)
Mild (FEV1 ≥80% predicted) 3 (1.4) 4 (2.1) 4 (2.0) 3 (2.7) 14 (1.9)
Moderate (FEV1 50–<80% predicted) 154 (71.0) 123 (63.1) 129 (63.2) 71 (62.8) 477 (65.4)
Severe (FEV1 30–<50% predicted) 58 (26.7) 61 (31.3) 68 (33.3) 38 (33.6) 225 (30.9)
Very severe (FEV1 <30% predicted) 2 (0.9) 7 (3.6) 3 (1.5) 1 (0.9) 13 (1.8)
Mean COPD durationd (SD), years 5.8 (5.3) 6.3 (6.2) 5.6 (5.3) 6.4 (6.3) 6.0 (5.7)
Notes: aThe total score was the sum of eight CAT item scores (range: 0–40). bNumber of pack-years smoked = (number of cigarettes per day/20) × number of years
smoked. cBased on post-bronchodilator FEV1.
dGFF MDI 18/9.6 µg, N=216; GP MDI 18 µg, N=195; FF MDI 9.6 µg, N=202; placebo MDI, N=113; overall N=726.
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second;
FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ICS, inhaled
corticosteroid; ITT, intent-to-treat; MDI, metered dose inhaler; SD, standard deviation.
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A patients were included. However, lung function data for
GOLD category A patients in the PINNACLE-1 study,
including the open-label tiotropium DPI arm, are shown in
Table S2.
The analyses of lung function by GOLD category
were specified in an integrated statistical analysis plan
that was developed after the reporting of data from
PINNACLE-1 and -2, but prior to the unblinding of
PINNACLE-4. All analyses were interpreted according
to a nominal significance level of 0.05. No adjustment
for multiplicity was applied, as type I error was con-
trolled within individual studies. The lung function end-
points were analyzed using a linear repeated measures
model with an unstructured covariance matrix, which
included the following covariates: baseline FEV1, percent
reversibility to albuterol sulfate, study (PINNACLE-1/
PINNACLE-2/PINNACLE-4), treatment, visit, and
treatment-by-visit interaction.
Table 2 Lung Function Endpoints for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (ITT Population)
GFF MDI 18/9.6 µg GP MDI 18 µg FF MDI 9.6 µg Placebo MDI
Baseline FEV1, L
n 216 195 204 113
Mean (SD) 1.393 (0.466) 1.345 (0.507) 1.323 (0.483) 1.329 (0.491)
Change from baseline in morning pre-dose trough FEV1, mL
At Week 24
n 197 177 178 96
LSM (SE) 106 (13.4) 52 (14.2) 44 (14.1) –82 (19.0)
Treatment difference for GFF MDI vs monocomponents and placebo MDI
LSM (95% CI) NA 54 (16, 92)* 62 (25, 100)* 188 (143, 234)**
Over 24 weeks
n 214 191 199 107
LSM (SE) 134 (10.1) 72 (10.7) 75 (10.6) –49 (14.2)
Treatment difference for GFF MDI vs monocomponents and placebo MDI
LSM (95% CI) NA 62 (33, 90)** 59 (31, 87)** 183 (149, 217)**
Peak change from baseline in FEV1 within 2 hrs post-dose, mL
At Week 24
n 198 177 179 96
LSM (SE) 335 (15.0) 210 (15.8) 230 (15.7) 28 (21.1)
Treatment difference for GFF MDI vs monocomponents and placebo MDI
LSM (95% CI) NA 124 (82, 167)** 104 (62, 147)** 307 (256, 358)**
Over 24 weeks
n 216 195 204 113
LSM (SE) 357 (10.9) 221 (11.4) 275 (11.3) 57 (15.1)
Treatment difference for GFF MDI vs monocomponents and placebo MDI
LSM (95% CI) NA 136 (106, 167)** 83 (52, 113)** 300 (264, 336)**
Notes: *p<0.01; **p<0.0001.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD,
Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; NA, not applicable; MDI, metered dose
inhaler; SD, standard deviation; SE, standard error.
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Results
Baseline Demographics and Clinical
Characteristics
Of the 4983 patients who were included in the pooled
ITT population, 729 (14.6%) were GOLD category A,
3693 (74.1%) were GOLD category B, 73 (1.5%) were
GOLD category C, and 473 (9.5%) were GOLD category
D (15 patients had missing data). The pooled GOLD
category A safety population included 730 patients (one
additional patient in the FF MDI treatment arm; this
patient had entered multiple studies and was included
only for the first of these in the ITT population, but
was included for both instances in the safety population,
as these periods were not overlapping).
The mean age (standard deviation [SD]) of GOLD category
A patients in the pooled ITT population was 65.5 (7.6) years.
The majority of patients were male (72.7%), White (59.4%),
and 65.4% had moderate airflow obstruction (post-
bronchodilator FEV1 50–<80% predicted). Approximately one
third (36.1%) of patients were Asian or were current smokers
(32.8%; Table 1). Themean total CATscore (SD)was 6.5 (2.2),
and the mean COPD duration (SD) was 6.0 (5.7) years. Despite
being GOLD category A, 30.2% of patients were using an ICS
at baseline and were allowed to continue its use throughout the
study. Baseline demographics and clinical characteristics were
generally similar across treatment groups (Table 1).
Change from Baseline in Morning
Pre-Dose Trough FEV1
In GOLD category A patients, GFF MDI significantly
improved change from baseline in morning pre-dose
trough FEV1 at Week 24 versus GP MDI (least squares
mean [LSM] difference 54 mL; p=0.0053), versus FF MDI
(LSM difference 62 mL; p=0.0013), and versus placebo
MDI (LSM difference 188 mL; p<0.0001). The findings
over 24 weeks were consistent with those at Week 24, with
significant improvements for GFF MDI versus GP MDI
(LSM difference 62 mL), FF MDI (LSM difference
59 mL), and placebo MDI (LSM difference 183 mL; all
p<0.0001; Table 2). The benefits of GFF MDI over mono-
components and placebo MDI were observed at all time
points (Figure 2).
Peak Change from Baseline in FEV1
GFF MDI improved peak change from baseline in
FEV1 within 2 hrs post-dose at Week 24 versus GP
MDI (LSM difference 124 mL), versus FF MDI (LSM
difference 104 mL), and versus placebo MDI (LSM
difference 307 mL; all p<0.0001). The findings over
24 weeks were consistent with those at Week 24, with
significant improvements reported for GFF MDI versus
GP MDI (LSM difference 136 mL), versus FF MDI
(LSM difference 83 mL), and versus placebo MDI
(LSM difference 300 mL; p<0.0001; Table 2).
Furthermore, the benefits of GFF MDI over monocom-
ponents and placebo MDI were observed at all time-
points (Figure 3).
Safety
In the GFF MDI group, 56.7% of GOLD category
A patients experienced a TEAE throughout the studies,
and 11.1% experienced a TEAE related to study
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treatment, in the opinion of the investigator. The most
common TEAEs in the GFF MDI group were upper
respiratory tract infection (6.9%) and viral upper respira-
tory tract infection (6.0%). Sixteen patients (7.4%) had
serious TEAEs with GFF MDI, and four patients (1.8%)
experienced a serious TEAE related to study treatment, in
the opinion of the investigator. The most common serious
TEAE was worsening of COPD, which occurred in seven
patients (3.2%) in the GFF MDI treatment arm.
A total of 36 patients (4.9%) discontinued from the
study early due to TEAEs, with the highest incidence of
discontinuations due to TEAEs in the placebo MDI group
(7.1%). One death occurred in GOLD category A patients
(FF MDI group; probable cardiovascular cause). The
TEAE profile of GFF MDI in GOLD category A patients
was generally similar to that of the monocomponents and
placebo MDI (Table 3), and was consistent with the over-
all patient population in the PINNACLE studies.9,11
Discussion
This pooled analysis of the PINNACLE-1, -2, and -4 studies
evaluated the lung function efficacy and safety of the LAMA/
LABA FDC GFF MDI in GOLD category A patients.
Consistent with the findings in the overall population, the
majority of whom were GOLD category B (74.1%), GFF
MDI improved lung function outcomes versus monocompo-
nents and placebo in GOLD category A patients, with
a magnitude of improvement that was comparable with the
overall population.9,11 Furthermore, improvements with GFF
MDI versus placebo for morning pre-dose trough FEV1 at
Week 24 and over 24 weeks exceeded the suggested minimal
clinically important difference of 100 mL (≥183 mL).14
Findings were consistent with a previous pooled analysis of
PINNACLE-1 and -2, which showed that lung function bene-
fits with GFF MDI were independent of baseline symptom
burden.15 Our findings with GFF MDI are also generally
consistent with a pooled post hoc analysis of tiotropium + olo-
daterol soft mist inhaler versus placebo and tiotropium mono-
therapy inGOLD category A patients with moderate-to-severe
COPD, which also found lung function improvements were
similar between GOLD groups.16 The lung function benefits
from LAMA/LABA therapy need to be weighed against the
known class effects of these bronchodilators.2
GOLD category A patients have a low symptom burden
and low exacerbation risk and, therefore, there is limited
capacity for improvements in symptoms, health-related quality
Table 3 Summary of TEAEs for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (Safety Population)
Number of Patients with a TEAE (%)
[Number of TEAEs]
GFF MDI 18/9.6 µg
(N=217)
GP MDI 18 µg
(N=195)
FF MDI 9.6 µg
(N=205)a
Placebo MDI
(N=113)
Overall
(N=730)
≥1 TEAE 123 (56.7) [244] 106 (54.4) [274] 112 (54.6) [248] 70 (61.9) [164] 411 (56.3) [930]
TEAEs related to study treatmentb 24 (11.1) [30] 20 (10.3) [29] 19 (9.3) [25] 12 (10.6) [20] 75 (10.3) [104]
Serious TEAEs 16 (7.4) [19] 7 (3.6) [10] 15 (7.3) [19] 7 (6.2) [10] 45 (6.2) [58]
Serious TEAEs related to study treatmentb 4 (1.8) [4] 3 (1.5) [4] 0 1 (0.9) [1] 8 (1.1) [9]
TEAEs leading to early discontinuation 12 (5.5) [16] 9 (4.6) [19] 7 (3.4) [9] 8 (7.1) [9] 36 (4.9) [53]
Deaths 0 0 1 (0.5)c 0 1 (0.1)
TEAEs occurring in ≥3% of patients in any treatment arm (preferred term), n (%) [events]
Viral upper RTI 13 (6.0) [17] 19 (9.7) [24] 15 (7.3) [16] 6 (5.3) [7] 53 (7.3) [64]
Upper RTI 15 (6.9) [16] 11 (5.6) [12] 10 (4.9) [12] 9 (8.0) [9] 45 (6.2) [49]
Cough 3 (1.4) [3] 9 (4.6) [10] 1 (0.5) [1] 4 (3.5) [5] 17 (2.3) [19]
Bronchitis 4 (1.8) [4] 6 (3.1) [6] 1 (0.5) [1] 5 (4.4) [5] 16 (2.2) [16]
Dyspnea 1 (0.5) [1] 5 (2.6) [6] 5 (2.4) [5] 4 (3.5) [4] 15 (2.1) [16]
COPDd 7 (3.2) [7] 2 (1.0) [2] 1 (0.5) [1] 4 (3.5) [4] 14 (1.9) [14]
Diarrhea 2 (0.9) [2] 1 (0.5) [1] 2 (1.0) [3] 4 (3.5) [5] 9 (1.2) [11]
Hypertension 0 2 (1.0) [2] 2 (1.0) [2] 5 (4.4) [5] 9 (1.2) [9]
Notes: aOne patient who was included in multiple studies was included in the safety population twice. bPossibly, probably, or definitely related, rated as per investigator’s
judgment prior to unblinding. cProbable cardiovascular cause during the treatment period. dWorsening of COPD defined as a COPD exacerbation since the patient’s last
visit. COPD exacerbations were only recorded as an adverse event if they were considered to be a serious TEAE.
Abbreviations: COPD, chronic obstructive pulmonary disease; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; GP, glycopyrrolate; MDI, metered dose inhaler; RTI, respiratory tract infection; TEAE, treatment-emergent adverse event.
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of life, and exacerbation outcomes in these patients.
Corresponding with this, a previous pooled analysis of the
PINNACLE-1 and -2 studies showed that improvements in St
George’s Respiratory Questionnaire score, rescue medication
use, and the rate of moderate/severe COPD exacerbations with
GFF MDI versus monocomponents and placebo MDI
increased with higher baseline CAT scores.15
GFFMDI was well tolerated with no new or unexpected
safety findings in GOLD category A patients compared
with the overall population.9,11 The TEAE profile of GFF
MDI was generally comparable to that of the LAMA and
LABA monocomponents and placebo MDI.
Conclusion
GFF MDI showed significant improvements in lung func-
tion compared with the monocomponent MDIs and placebo
MDI and was well tolerated in GOLD category A patients.
Improving lung function is a key treatment goal in these
patients and, therefore, dual long-acting bronchodilator
therapy may be an appropriate alternative treatment option
for GOLD category A patients.
Abbreviations
AE, adverse event; CAT, COPD Assessment Test; DPI,
dry-powder inhaler; FDC, fixed-dose combination; FEV1,
forced expiratory volume in 1 second; FF, formoterol
fumarate; GFF, glycopyrrolate/formoterol fumarate;
GOLD, Global Initiative for Chronic Obstructive Lung
Disease; GP, glycopyrrolate; ICS, inhaled corticosteroid;
ITT, intent-to-treat; LABA, long-acting β2-agonist;
LAMA, long-acting muscarinic antagonist; LSM, least
squares mean; MDI, metered dose inhaler; mMRC, mod-
ified Medical Research Council; SD, standard deviation;
SE, standard error; TEAE, treatment-emergent adverse
event.
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